Financial
XTL Biopharmaceuticals Announces Six-Month Performance
Published in Hepatitis Weekly, October 15th, 2001
XTL Biopharmaceuticals Ltd. (XTL) has announced interim results for the six months ended June 30, 2001. XTL-001 for hepatitis B advanced into multicenter, Phase II combination studies with standard therapy XTL-002 for hepatitis C entered a Phase I trial in Israel and the U.S. Received two milestone payments from an undisclosed corporate partner for an IND filing Acquired a 20% stake in iviGene Corp. to identify novel drug targets for treating a broad range of infectious diseases Formed a discovery, development and commercialization agreement with Dyax Corp. for the treatment of selected fungal...
Highlights:
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2001-10-15)
More Articles from Hepatitis Weekly
- Immunization
Routine Hepatitis A Vaccine Programs Needed For At-Risk Populations - Viral Genomics
TTV Reinfection In Hemophiliacs Supports Transfusion Role In Transmission - Emerging Infectious Disease
New Chicken Virus Resembles Hepatitis E Virus In Humans - Kidney Transplantation
Hepatitis B Influences Outcomes After Renal Transplants - At-Risk Populations
Oral Piercings Gaining Popularity - Hepatitis E Virus
Vaccine To Undergo Phase II Clinical Trial In Nepal - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
